SKSenjuti Kabir

Senjuti Kabir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Senjuti Kabir has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pooled sputum testing for the detection of pulmonary tuberculosis by Xpert ® MTB/RIF Ultra: a multi-site cross-sectional diagnostic evaluation study in Bangladesh

    by S. M. Mazidur Rahman, Sohag Miah, Tanjina Rahman, Sabrina Choudhury, Noshin Nawer Ruhee, Senjuti Kabir, Mohammad Khaja Mafij Uddin, Shahriar Ahmed, Vibol Iem, Rachel Louise Byrne, et al.

    Background: Xpert ® MTB/RIF Ultra (Xpert Ultra) is a WHO recommended molecular test for rapid tuberculosis (TB) detection, but cartridge cost limits large-scale use of Xpert Ultra in high TB burden, resource-constrained countries. This study assessed the diagnostic performance of Xpert Ultra on pooled sputum for detection of pulmonary TB (PTB)in Bangladesh. Methods: Between July 2024 and February 2025, adults with presumptive PTB were prospectively enrolled from primary and secondary healthcare facilities through facility-based case finding, and from urban slum communities through community-based case finding. Participants provided two sputum samples, one for individual and pooled Xpert Ultra testing, and another for culture. Pooled and individual Xpert Ultra results were compared to the microbiological reference standard of culture. Cost analysis was performed by comparing cartridge usage between individual and pooled Xpert Ultra testing. Results: A total of 3043 individuals were tested individually and as part of 771 pooled samples. Compared with culture, the overall sensitivities of pooled and individual Xpert Ultra were 85.8% (95% CI: 79.8-90.6) and 89.2% (83.7-93.4), respectively, while specificities were 98.9% (98.4-99.2) and 98.1% (97.5-98.6). Pooled Xpert Ultra detected 100% of the high, medium, and low burden categories identified by individual testing, but showed lower detection for very low (81.8%) and trace (31.4%). Compared with individual testing, pooled testing reduced cartridge use and cost by 55.8%. Conclusions: Pooled sputum testing with Xpert Ultra demonstrated high diagnostic performance similar to individual testing, while substantially reducing the cartridge costs. This approach offers a scalable molecular TB testing in resource-limited, high-burden countries such as Bangladesh.


  • Open Access

    Evaluation of a Fluorescence Immunoassay-Based IGRA for Latent Tuberculosis Diagnosis: A Simplified, Cost-Effective Alternative

    by Mohammad Khaja Mafij Uddin, Aar Rafi Mahmud, Afsana Akter Rupa, Ashabul Islam, Jahin Fairuj Oishi, Jannatul Ferdous, Rumana Nasrin, Syed Mohammad Mazidur Rahman, Senjuti Kabir, Shahriar Ahmed, et al.

    Approximately 25% of the global population is estimated to have latent tuberculosis infection (LTBI), with a 5–10% lifetime risk of progression to active disease. Although interferon-gamma release assays (IGRAs) are widely used for LTBI diagnosis, their high cost and operational complexity limit large-scale implementation in resource-limited settings. This study evaluated the diagnostic performance of a low-complexity, rapid, fluorescence-based point-of-care assay, ichroma IGRA-TB, for LTBI detection. A total of 300 participants enrolled at TB Screening and Treatment Centers and the Dhaka Hospital of icddr,b were categorized as healthy controls (n = 130), household contacts of TB patients (n = 70), GeneXpert MTB/RIF Ultra-positive active TB patients (n = 80), or individuals with a previous history of TB (n = 20). ichroma IGRA-TB was compared with QuantiFERON-TB Gold Plus (QFT-Plus) across all groups. Overall agreement between ichroma IGRA-TB and QFT-Plus was 91.9%, with a Cohen’s kappa of 0.83, indicating almost perfect concordance. Using culture as a surrogate reference standard, QFT-Plus demonstrated higher sensitivity (74.6%) than ichroma IGRA-TB (69.0%). Overall, ichroma IGRA-TB demonstrates high agreement with QFT-Plus and acceptable sensitivity, supporting its potential as a near-point-of-care tool for LTBI screening in resource-constrained settings.


  • Open Access

    Centrifugation Versus Centrifugation-Free Stool Processing: Can the Simple One-Step Method Reliably Diagnose Pediatric Pulmonary Tuberculosis Using Xpert MTB/RIF Ultra?

    by S. M. Mazidur Rahman, Senjuti Kabir, Sabrina Choudhury, Sohag Miah, Tanjina Rahman, Jahid Hasan, Mohammad Khaja Mafij Uddin, Arifa Nazneen, Shahriar Ahmed, Aung Kya Jai Maug, et al.

    Background/Objectives: Stool-based GeneXpert testing has become a useful approach for diagnosing pediatric pulmonary tuberculosis (PTB). This study compared two stool-processing methods, centrifugation-based processing (CBP) and simple one-step (SOS), for detecting PTB in children using Xpert MTB/RIF Ultra (Ultra). Methods: Children with presumptive PTB were screened cross-sectionally, and stool samples were collected and tested with Ultra using the CBP method from March 2022 to December 2024 across seven divisions of Bangladesh. A subset of stool samples (n = 281) that tested positive (n = 191) and negative (n = 90) by the CBP method were re-tested again with the same sample by Ultra using the SOS method. The results of the Ultra with SOS-processed stool were compared with the CBP method to evaluate overall agreement and detection efficiency across different bacterial burdens. Results: The SOS method detected 97 of 191 CBP-positive samples, resulting in a positive percentage agreement of 50.8% (95% CI: 43.5–58.1). All 90 Ultra-negative stool were also negative by the SOS method, yielding a negative percentage agreement of 100% (95% CI: 96.0–100.0). Overall agreement between the methods was 66.6% (Kappa: 0.398). The SOS method detected 100% of high- (4/4) and medium- (7/7), 97.3% (36/37) of low-, and 83.3% (35/42) of very-low-bacterial-burden samples, but only 14.9% (15/101) of the trace-detected samples that were identified by the CBP method. Conclusions: Stool testing with Ultra using the SOS processing method missed a significant number of the most prevalent form of child TB—the ‘trace-detected’ category identified by the CBP method. For increased detection of childhood TB nationwide, the national program should prioritize the use of Ultra on stool samples processed by the CBP method.


  • Open Access

    OMNIgene.SPUTUM for transporting sputum in ambient temperature for tuberculosis testing: Bangladesh experience

    by Senjuti Kabir, Sabrina Choudhury, Mohammad Khaja Mafij Uddin, Fahim Ather, Syed Mohammad Mazidur Rahman, Pronab Kumar Modak, Mohammad Samsuddoha Sarker Shanchay, Tanjina Rahman, Shahriar Ahmed, Sayera Banu

  • Open Access

    A study protocol on assessing the acceptance and effectiveness of a digital adherence technology for TB preventive treatment in Bangladesh

    by Pushpita Samina, Rifat Haidar, Tasmia Ibrahim, Tanjina Rahman, Mohammad Shahnewaz Sarker, Syada Samsia Noor, Shahriar Ahmed, Mohammad Khaja Mafij Uddin, Senjuti Kabir, Sayera Banu

    Background: Adherence to tuberculosis preventive treatment (TPT) remains a significant challenge in high-burden countries like Bangladesh, where approximately 44 million people are infected with latent tuberculosis. Methods/Design: This study protocol describes a mixed-methods observational study to evaluate “iDOTS,” a locally developed digital adherence technology adapted from 99DOTS, for monitoring and improving TPT adherence among adult household contacts of bacteriologically confirmed pulmonary TB patients. The study will be conducted in two districts in Bangladesh with similar geographical and societal characteristics, with Narsingdi as the intervention site and Manikganj as the control site. Applying the Unified Theory of Acceptance and Use of Technology (UTAUT), we will assess technology acceptance, implementation challenges, and effectiveness through quantitative and qualitative approaches. The quantitative component will compare TPT adherence between iDOTS users and non-users, while qualitative interviews will explore user experiences and attitudes among healthcare providers and patients. Adherence will be verified through a combination of digital records, self-reports, and random isoniazid urine testing. Discussion: With an estimated sample size of 422 patients and 77 healthcare providers, this study aims to generate evidence that if digital adherence technologies can strengthen TPT implementation in resource-limited settings. The findings will address critical gaps in the TPT cascade and inform strategies for scaling up TPT nationally, ultimately supporting global efforts to reduce the TB disease burden through effective preventive measures. Trial registration: ‘Not applicable’

  • Open Access

    Diagnostic Performance of Different Laboratory Methods for the Detection of Extrapulmonary Tuberculosis

    by Mohammad Khaja Mafij Uddin, Fahim Ather, Senjuti Kabir, Arfatur Rahman, Sabrina Choudhury, Rumana Nasrin, Tanjina Rahman, S. M. Mazidur Rahman, Shahriar Ahmed, Sayera Banu

    Accurate and appropriate extrapulmonary tuberculosis (EPTB) diagnosis remains challenging due to its paucibacillary nature, requirement of invasive collection procedures, and lack of sensitive tests. This study investigated the diagnostic performance of different methods for the diagnosis of EPTB. A total of 1340 EPTB specimens were collected from presumptive EPTB patients from four different hospitals between November 2015 and March 2017. The collected specimens were tested with AFB microscopy, culture, Xpert MTB/RIF assay (Xpert), and MTBDRplus assay. Among the 1340 EPTB specimens, 49 (3.66%), 141 (10.52%), 166 (12.39%), and 154 (11.49%) were positive in AFB microscopy, culture, Xpert MTB/RIF, and MTBDRplus assay, respectively. A total of 194 (14.9%) cases were found positive in at least one of these methods. Using culture as a reference standard, the sensitivity and specificity of AFB microscopy, Xpert MTB/RIF, and MTBDRplus assay were: 27.0%/99.1%, 83.7%/96.0%, and 79.4%/96.5%, respectively. Compared to the composite reference standard, the sensitivity of culture, AFB microscopy, Xpert MTB/RIF, and MTBDRplus assay was 72.7%, 25.3%, 85.6%, and 79.4%, respectively, with a specificity of 100% for all the methods. The Xpert MTB/RIF assay showed the highest sensitivity compared to other methods. Considering the short turnaround time and promising findings, Xpert MTB/RIF assay should be integrated into national TB guidelines as a routine diagnostic test.


  • Open Access

    Xpert MTB/RIF Ultra assay for the detection of Mycobacterium tuberculosis in people with negative conventional Xpert MTB/RIF but chest imaging suggestive of tuberculosis in Dhaka, Bangladesh

    by Samanta Biswas, Mohammad Khaja Mafij Uddin, Kishor Kumar Paul, Fahim Ather, Shahriar Ahmed, Rumana Nasrin, Senjuti Kabir, Scott K Heysell, Sayera Banu


  • Open Access

    Genetic diversity and characterization of M. tuberculosis isolates causing extrapulmonary tuberculosis in Bangladesh

    by Mohammad Khaja Mafij Uddin, Fahim Ather, Arfatur Rahman, Rumana Nasrin, S.M. Mazidur Rahman, Senjuti Kabir, Carole Chedid, Shahriar Ahmed, Sayera Banu


  • Open Access

    Social Enterprise Model (SEM) for private sector tuberculosis screening and care in Bangladesh

    by Sayera Banu, Farhana Haque, Shahriar Ahmed, Sonia Sultana, Mahfuzur Rahman, Razia Khatun, Kishor Kumar Paul, Senjuti Kabir, S. M. Mazidur Rahman, Rupali Sisir Banu, et al.

    Background: In Bangladesh, about 80% of healthcare is provided by the private sector. Although free diagnosis and care is offered in the public sector, only half of the estimated number of people with tuberculosis are diagnosed, treated, and notified to the national program. Private sector engagement strategies often have been small scale and time limited. We evaluated a Social Enterprise Model combining external funding and income generation at three tuberculosis screening centres across the Dhaka Metropolitan Area for diagnosing and treating tuberculosis. Methods and findings: The model established three tuberculosis screening centres across Dhaka Metropolitan Area that carried the icddr,b brand and offered free Xpert MTB/RIF tests to patients visiting the screening centres for subsidized, digital chest radiographs from April 2014 to December 2017. A network of private and public health care providers, and community recommendation was formed for patient referral. No financial incentives were offered to physicians for referrals. Revenues from radiography were used to support screening centres’ operation. Tuberculosis patients could choose to receive treatment from the private or public sector. Between 2014 and 2017, 1,032 private facilities networked with 8,466 private providers were mapped within the Dhaka Metropolitan Area. 64, 031 patients with TB symptoms were referred by the private providers, public sector and community residents to the three screening centres with 80% coming from private providers. 4,270 private providers made at least one referral. Overall, 10,288 pulmonary and extra-pulmonary tuberculosis cases were detected and 7,695 were bacteriologically positive by Xpert, corresponding to 28% of the total notifications in Dhaka Metropolitan Area. Conclusion: The model established a network of private providers who referred individuals with presumptive tuberculosis without financial incentives to icddr,b’s screening centres, facilitating a quarter of total tuberculosis notifications in Dhaka Metropolitan Area. Scaling up this approach may enhance national and international tuberculosis response.


  • Open Access

    Multicenter analysis of sputum microbiota in tuberculosis patients

    by Claudia Sala, Andrej Benjak, Delia Goletti, Sayera Banu, Jesica Mazza-Stadler, Katia Jaton, Philippe Busso, Sille Remm, Marion Leleu, Jacques Rougemont, et al.

    The impact of tuberculosis and of anti-tuberculosis therapy on composition and modification of human lung microbiota has been the object of several investigations. However, no clear outcome has been presented so far and the relationship between M. tuberculosis pulmonary infection and the resident lung microbiota remains vague. In this work we describe the results obtained from a multicenter study of the microbiota of sputum samples from patients with tuberculosis or unrelated lung diseases and healthy donors recruited in Switzerland, Italy and Bangladesh, with the ultimate goal of discovering a microbiota-based biomarker associated with tuberculosis. Bacterial 16S rDNA amplification, high-throughput sequencing and extensive bioinformatic analyses revealed patient-specific flora and high variability in taxon abundance. No common signature could be identified among the individuals enrolled except for minor differences which were not consistent among the different geographical settings. Moreover, anti-tuberculosis therapy did not cause any important variation in microbiota diversity, thus precluding its exploitation as a biomarker for the follow up of tuberculosis patients undergoing treatment.